[Frontiers in Bioscience S5, 766-773, January 1, 2013]

STIM1 and Orai in cardiac hypertrophy and vascular proliferative diseases

Anne-Marie Lompre1,2,3, Ludovic Benard4, Youakim Saliba1,2,3, Fleur Aubart1,2,3, Jeremy Fauconnier5, Jean-Sebastien Hulot1,2,3,4

1Inserm UMRS 956- Paris, F75013, France, 2Universite Pierre et Marie Curie UMRS956, Paris, F75013, France, 3Institute for Cardiac Metabolism and Nutrition-Paris,75013,France, 4Cardiovascular Research Institute, Mount Sinai School of Medicine, New York, 5Inserm U1046, Universite Montpellier 1, Universite Montpellier 2, Montpellier, F34000, France


1. Abstract
2. Introduction
3. STIM and ORAI in cardiac pathophysiology
3.1. Roles and regulation of calcium in cardiac myocytes
3.2. SOCE, STIM1 and Orai in normal and pathological cardiac myocytes
3.3. Role of STIM1 in controling cardiomyocyte growth
3.4. TRPC versus Orai
4. STIM and Orai in vascular proliferative diseases
4.1. SOCE in vascular proliferative diseases
4.2. Implication of STIM and Orai in vascular proliferativre diseases
4.3. TRPC versus Orai
5. STIM controls a new transcription pathway
6. Conclusions
7. Acknowledgments
8. References


Cardiac hypertrophy and vascular proliferative diseases are associated with major alterations in calcium homeostasis and calcium signaling. The recent discovery of STIM and Orai has generated great enthusiasm concerning the role of these proteins in the cardiovascular system. We will review the major results concerning the existence and the role of these proteins in the cardiovascular system in normal and pathological situations and their implication in cardiovascular remodeling.